MedinCell S.A.

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 12:55:00 2026-03-12 pm EDT			Pre-market 03:15:44 am
20.80 ^EUR	-5.71%		20.63	-0.82%

Mar. 06	Atos, Medincell, Spie... Stocks to Watch Today in Paris
Mar. 06	Medincell Raises 48 Million Euros at 20.35 EUR per Share

Medincell S.A. Reports Sales Results for the Fourth Quarter and Full 2025

Published on 01/28/2026 at 09:21 am EST

S&P Capital IQ

MEDINCELL S.A.

-5.71%

Medincell S.A. reported sales results for the fourth quarter and Full 2025. For the quarter, the company net sales reached $55 million. For the year 2025 net sales reached $191 million.

Latest news about MedinCell S.A.

Mar. 06	Atos, Medincell, Spie... Stocks to Watch Today in Paris
Mar. 06	Medincell Raises 48 Million Euros at 20.35 EUR per Share
Mar. 06	MedinCell completes EUR 48 mln private placement	RE
Mar. 06	Medincell
Mar. 05	MedinCell S.A. announced that it has received ?48 million in funding from SITAM Belgique SA, Mirova SA, Perceptive Advisors LLC, Kurma Partners SA, Affinity Asset Advisors, LLC, Polar Capital Holdings Plc	CI
Mar. 05	GTT, JCDecaux, Medincell... Stocks to Watch Tomorrow in Paris -
Mar. 05	Medincell Unveils Private Placement
Mar. 05	MedinCell launches a private placement for international institutional investors	RE
Mar. 05	Jefferies Remains Positive on Medincell Despite Lowered Price Target
Feb. 23	Medincell Rises Following Positive Decision from U.S. FDA
Feb. 23	Exosens, Vinci, Dassault Systèmes... Stocks to Watch Today in Paris
Feb. 23	FDA Accepts NDA Filing for Olanzapine LAI (Medincell)
Feb. 23	FDA Accepts NDA Filing for Olanzapine LAI (Medincell)
Feb. 20	Teva Pharmaceuticals Announces U.S. Food and Drug Administration Accepts Teva's New Drug Application for Olanzapine Extended-Release Injectable Suspension (TEV-749) for the Once-Monthly Treatment of Schizophrenia in Adults	CI
Feb. 18	Mirova Holds Less Than 5% of Voting Rights in MedinCell

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2025, the company had a portfolio of 2 products in phase III clinical development and 3 products in preclinical development.

Employees

145

Sector

Pharmaceuticals

Calendar

Jun. 16 - Earnings release - Annual 2026

More about the company